Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 01, 2023

SELL
$86.5 - $103.97 $1,038 - $1,247
-12 Reduced 0.52%
2,305 $215,000
Q2 2023

Aug 04, 2023

SELL
$69.96 - $97.84 $559 - $782
-8 Reduced 0.34%
2,317 $206,000
Q1 2023

May 05, 2023

BUY
$104.9 - $126.78 $5,140 - $6,212
49 Added 2.15%
2,325 $249,000
Q4 2022

Jan 25, 2023

SELL
$99.42 - $131.97 $198 - $263
-2 Reduced 0.09%
2,276 $278,000
Q3 2022

Nov 04, 2022

BUY
$84.03 - $110.23 $84 - $110
1 Added 0.04%
2,278 $235,000
Q2 2022

Aug 01, 2022

SELL
$78.08 - $117.61 $546 - $823
-7 Reduced 0.31%
2,277 $212,000
Q1 2022

May 05, 2022

BUY
$102.18 - $135.75 $10,320 - $13,710
101 Added 4.63%
2,284 $268,000
Q4 2021

Feb 03, 2022

SELL
$127.1 - $169.66 $127 - $169
-1 Reduced 0.05%
2,183 $294,000
Q3 2021

Nov 04, 2021

SELL
$112.67 - $176.92 $32,336 - $50,776
-287 Reduced 11.61%
2,184 $348,000
Q2 2021

Aug 09, 2021

BUY
$121.62 - $145.29 $17,026 - $20,340
140 Added 6.01%
2,471 $325,000
Q1 2021

May 11, 2021

SELL
$124.92 - $173.33 $148,404 - $205,916
-1,188 Reduced 33.76%
2,331 $300,000
Q4 2020

Jan 27, 2021

SELL
$151.2 - $182.76 $9,828 - $11,879
-65 Reduced 1.81%
3,519 $587,000
Q3 2020

Nov 12, 2020

SELL
$134.29 - $154.32 $12,220 - $14,043
-91 Reduced 2.48%
3,584 $553,000
Q1 2020

May 07, 2020

BUY
$97.01 - $145.11 $26,192 - $39,179
270 Added 7.93%
3,675 $413,000
Q4 2019

Jan 24, 2020

BUY
$91.45 - $139.12 $4,115 - $6,260
45 Added 1.34%
3,405 $474,000
Q3 2019

Oct 29, 2019

BUY
$95.8 - $118.9 $36,308 - $45,063
379 Added 12.71%
3,360 $324,000
Q2 2019

Jul 19, 2019

BUY
$107.11 - $132.09 $319,294 - $393,760
2,981 New
2,981 $343,000

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.61B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Jgp Global Gestao De Recursos Ltda. Portfolio

Follow Jgp Global Gestao De Recursos Ltda. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jgp Global Gestao De Recursos Ltda., based on Form 13F filings with the SEC.

News

Stay updated on Jgp Global Gestao De Recursos Ltda. with notifications on news.